INSIGHTS ON PHARMA LOGISTICS

• What Makes A Successful CGT Channel Strategy? Key Considerations For CGT Developers

  Distribution model, customer network, and order submission are interlocking choices for cell and gene therapies, shaped by handling demands, treatment setting, and patient population.

• Commercial Readiness: The ROI Of Defragmented Supply Chains

  Clinical-stage supply chains often hide costs that emerge at commercial scale. Standardizing systems, documentation, and providers can reduce variability and improve long-term performance.

• Extended Manufacturability: Why Cryopreservation Is A Commercial Enabler

  Cryopreserved starting materials separate collection from manufacturing, improving capacity planning, enabling broader geographic reach, and redefining commercial readiness for cell therapies.

• Building a Global Manufacturing Network: "Dual-Sourcing" Commercial Strategies

  EU entry after FDA approval puts launch timing and supply continuity at risk. QP release, importation pathways, and distributed manufacturing networks all shape whether a biologic reaches the market predictably.

• Integrated Services That Pass Inspections

  10/1/2026

  Standardized supply chain workflows reduce risk, protect biological integrity, and enable compliant scaling from clinical trials through commercialization.

• Ultra Low Temperature Packaging Solutions

  9/3/2026

  Maintaining product integrity is critical for ultra-low temperature therapies. Learn key lessons from a complex gene therapy launch.

• Global Complexity Demands Local Resilience

  8/31/2026

  With integrated capabilities spanning early development through commercial manufacturing, our U.S. network helps customers build greater supply chain resilience, navigate uncertainty, and create a more reliable path to market.

• 3 Decision Domains Shaping Sterile Drug Product Success

  8/28/2026

  In sterile development, the decisions with the greatest downstream consequences are rarely recognized as such when they are made. Examine how these choices shape program outcomes across the lifecycle.